Search Results
Oct 07, 2025, 09:00 ET Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
continues enrolling patients for the PIK3CA mutant cohort. Celcuity is also conducting its VIKTORIA-2 Phase 3 trial evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for HR+/HER2- advanced breast cancer, along with a Phase 1/2 trial combining gedatolisib with darolutamide
More news about: USA News Group
Oct 01, 2025, 09:00 ET Decisiv Names President Tim Hardin to the Role of Chief Executive Officer
leveraging data analytics and AI to drive innovation and growth. His experience also includes key positions at Solera, and ADP Dealer Services (now CDK Global). "We have a strong foundation and an exciting roadmap for 2025 and beyond," Hardin said. "You can expect several important
More news about: Decisiv, Inc.
Oct 01, 2025, 08:00 ET Immutable and Polygon Labs Supercharge Gaming Partnership with Dedicated Play Hub as Immutable Adopts Agglayer
will introduce innovative tools and incentives to onboard and retain top Web3 games, supporting sustainable growth across both Polygon PoS and Agglayer CDK-powered games.
More news about: Immutable
Sep 30, 2025, 09:00 ET FDA dos EUA aprova Inluriyo (imlunestrant) para adultos com câncer de mama avançado ou metastático ER+, HER2- e com mutação ESR1
mama metastático após recorrência com inibidor de aromatase adjuvante (IA), com ou sem inibidor de CDK4/6 prévio (21%), ou como tratamento de segunda linha após progressão com IA, com ou sem inibidor de CDK4/6 prévio (79%). "Isso representa um avanço importante para pacientes com
More news about: Eli Lilly do Brasil
Sep 25, 2025, 14:01 ET U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
as first-line treatment for MBC following recurrence on adjuvant aromatase inhibitor (AI), +/- prior CDK4/6 inhibitor (21%), or as second-line treatment for MBC following progression on AI, +/- prior CDK4/6 inhibitor (79%). "This represents an important advancement for patients with ESR1-mutated
More news about: Eli Lilly and Company
Sep 25, 2025, 03:30 ET Lonza's Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC
agreement centered around technology enabling dual-payload ADCUnique combination of Synaffix's exatecan-based technology with Qurient's CDK7 inhibitor AMSTERDAM and SEONGNAM-SI, South Korea ,
More news about: Synaffix
Sep 16, 2025, 17:31 ET KAT6 Inhibitors Market Poised for Significant Growth During the Forecast Period (2025-2040) | DelveInsight
target in estrogen receptor-positive (ER+) HER2-negative breast cancer, particularly in patients who have developed resistance to standard therapies like CDK4/6 inhibitors and endocrine treatments. Amplification of KAT6 occurs in approximately 10–15% of these patients, making it a promising target for overcoming
More news about: DelveInsight Business Research, LLP